NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Clinical trial NCT04930783 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04930783
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-03
- Primary completion
- 2027-12-31
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.